Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FT4NF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,618
Award facts
- Contract value 100% obligated
- $21,618.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp was awarded a delivery order contract on December 8, 2025, by the Defense Logistics Agency (DLA) for the supply of Dupixent 300 mg/2 ml pen auto-injectors with a ceiling value of $21,618.12. The contract employs firm fixed pricing and is classified as a non-competitive award with no set-aside designation. Performance will be executed from the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December 9, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026.
As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen provides an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies to military and veteran healthcare systems. Dupixent is a specialty biologic medication used for treating eczema, asthma, and other inflammatory conditions. This delivery order represents one of numerous competitively awarded transactions under the DLA Troop Support Medical umbrella contract, demonstrating the company's established capability to fulfill federal healthcare supply requirements. The DLA plans to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards, positioning AmerisourceBergen among key suppliers supporting the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities.
Quick answers
Who was awarded contract SPE2DR26FT4NF?
SPE2DR26FT4NF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FT4NF worth?
The government has obligated $21,618 on SPE2DR26FT4NF.
Is contract SPE2DR26FT4NF an order under another contract?
Yes. SPE2DR26FT4NF is a delivery order under SPE2DR25D3201, an indefinite delivery contract.
Was contract SPE2DR26FT4NF competed?
The extent of competition for SPE2DR26FT4NF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award